Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

This Progressive Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday

Author: Avi Kapoor | September 18, 2025 10:00am

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

  • HC Wainwright & Co. analyst Swayampakula Ramakanth downgraded Innate Pharma S.A. (NASDAQ:IPHA) from Buy to Neutral. Innate Pharma shares closed at $2.05 on Wednesday. See how other analysts view this stock.
  • Leerink Partners analyst Daina Graybosch downgraded Innate Pharma S.A. (NASDAQ:IPHA) from Outperform to Market Perform and slashed the price target from $10 to $2. Innate Pharma shares closed at $2.05 on Wednesday. See how other analysts view this stock.
  • Wells Fargo analyst Elyse Greenspan downgraded the rating for The Progressive Corporation (NYSE:PGR) from Overweight to Equal-Weight and lowered the price target from $327 to $265. Progressive shares closed at $243.61 on Wednesday. See how other analysts view this stock.

Considering buying IPHA stock? Here’s what analysts think:

Read This Next:

Photo via Shutterstock

Posted In: AVAV IPHA PGR RMD TSEM

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist